Rocket Pharmaceuticals, Inc. Proceeds from Issuance of Private Placement
Rocket Pharmaceuticals, Inc. (RCKT) reported Proceeds from Issuance of Private Placement of $188.88 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2023-11-07
- Rocket Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2022-12-31 was $108.14M.
- Rocket Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2021-12-31 was -$15.03M, a 105.35% decline year-over-year.
- Rocket Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2020-12-31 was $280.76M.
- Rocket Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2022 was $108.14M, a 854.69% increase from fiscal 2021.
- Rocket Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2021 was $11.33M, a 95.97% decline from fiscal 2020.
- Rocket Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2020 was $280.76M, a 57.94% increase from fiscal 2019.
- Rocket Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2019 was $177.76M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month | Proceeds from Issuance of Private Placement 12 month as first filed |
|---|---|---|---|---|
| 2023-09-30 | $188.88M 10-Q · filed 2023-11-07 | |||
| 2022-12-31 | $108.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $108.14M 10-K · filed 2023-02-28 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | -$15.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $11.33M 10-K · filed 2023-02-28 | $26.35M 10-K · filed 2022-02-28 | |
| 2021-09-30 | $26.35M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $280.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $280.76M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $177.76M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |